Title: Evaluation of the **Bordier/Gold Standard Diagnostics Strongyloidesratti**for the diagnosis of human strongyloidiasis (catalog/article # 9450)

Assay evaluation date: January 2014

Background: Many health care providers need to provide diagnosis for human strongyloidiasis and have trouble identifying a reliable kit to use. A panel of 124 sera previously tested in the CDC Strongyloides IgG assay was employed for this evaluation.The specimens (184) for the evaluation included:

(a) 61 Proven cases: Strongyloides positive, previously tested at CDC
(b) 80 Negative sera
(c) 44 Cross reactors: Sera positive for other diseases

Results(based on the cutoff established by the kit: the result is positive when the absorbance of the analyzed sample is higher than the absorbance of the weak positive provided by the kit)

GSD-Bordier kit for *Strongyloides*
(Strongyloidesratti EIA)

Sensitivity	Specificity
85% (52/61)	94% (116/124) Negatives and cross reactors
85% (52/61)	98% (78/80) Negatives only

Cross-Reactivity

Conditions	No of Sera Tested	No. of Positives	% Cross-reactivity
Negatives	80	2	3
Ascariasis	4	0	0
Cysticercosis	2	0	0
Echinococcosis	3	0	0
Fasciolosis	1	0	0
Hookworm	7	3	43
Hymenolopsis	2	1	50
Paragonimiasis	3	0	0
Schistosomiasis	2	0	0
Taeniosis	1	0	0
Toxocariosis	12	1	8
Trichinellosis	3	0	0
Trichuriasis	2	0	0
Tuberculosis	1	0	0

Conclusion: The kit produced by Bordier/Gold Standard Diagnostics for the diagnosis of human strongyloidiasisperformed well on the evaluation conducted at CDC and is acceptable for use.